SAN FRANCISCO--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) (the “Company”) today announced the
early tender results as of the Early Tender Time (as defined below) in
connection with its previously announced cash tender offer to purchase
up to $1,100,000,000 (the “Tender Cap”) combined aggregate purchase
price (the “Offer”) of its outstanding 6.000% Notes due 2041 (the
“6.000% Notes”), 7.650% Debentures due 2027 (the “7.650% Debentures”),
4.883% Notes due 2044 (the “4.883% Notes”), 4.750% Notes due 2021 (the
“4.750% Notes”) and 7.500% Notes due 2019 (the “7.500% Notes” and
together with the 6.000% Notes, the 7.650% Debentures, the 4.883% Notes
and the 4.750% Notes, the “Notes”, and each, a “series” of Notes).
On February 7, 2018, the Company commenced the Offer in accordance with
the terms and conditions set forth in the offer to purchase, dated
February 7, 2018 (the “Offer to Purchase”), and the related letter of
transmittal (the “Letter of Transmittal” and, together with the Offer to
Purchase, the “Offer Documents”), sent to holders of the Notes.
As of 5:00 p.m., New York City time, on February 21, 2018 (the “Early
Tender Time”), $909,632,000 aggregate principal amount of the Notes were
validly tendered and not validly withdrawn pursuant to the Offer, as set
forth in the table below:
Title of Security
|
|
CUSIP / ISIN Numbers
|
|
Principal Amount
Outstanding
|
|
Acceptance
Priority Level
|
|
Principal
Amount
Tendered as of
the
Early Tender
Time
|
|
Percent of
Outstanding
Principal Amount
Tendered(1)
|
|
|
|
|
|
|
|
|
|
|
|
6.000% Notes due 2041
|
|
58155QAE3 / US58155QAE35
|
|
$500,000,000
|
|
1
|
|
$187,797,000
|
|
37.6%
|
|
|
|
|
|
|
|
|
|
|
|
7.650% Debentures due 2027
|
|
581557AM7 / US581557AM75
|
|
$175,000,000
|
|
2
|
|
$8,404,000
|
|
4.8%
|
|
|
|
|
|
|
|
|
|
|
|
4.883% Notes due 2044
|
|
581557 BC8 / US581557BC84
|
|
$800,000,000
|
|
3
|
|
$388,425,000
|
|
48.6%
|
|
|
|
|
|
|
|
|
|
|
|
4.750% Notes due 2021
|
|
58155QAD5 / US58155QAD51
|
|
$600,000,000
|
|
4
|
|
$276,586,000
|
|
46.1%
|
|
|
|
|
|
|
|
|
|
|
|
7.500% Notes due 2019
|
|
581557 AX3 / US581557AX31
|
|
$350,000,000
|
|
5
|
|
$48,420,000
|
|
13.8%
|
|
|
|
|
|
|
|
|
|
|
|
(1) Rounded to the nearest one tenth of a percent.
|
|
|
|
|
|
|
|
|
|
|
|
The Company today also announced that it has amended the terms of the
Offer to provide that it will pay the Full Tender Offer Consideration
with respect to Notes purchased pursuant to the Offer (including Notes
tendered after the Early Tender Time other than the 7.500% Notes, which
the Company currently intends, but is not obligated, to redeem in full).
Tendered Notes will be accepted in the order of the acceptance priority
level for such series (in numerical priority order) as set forth in the
table above, with 1 being the highest acceptance priority level, and
based on whether the Notes are tendered at or before the Early Tender
Time or after the Early Tender Time, as described in the Offer to
Purchase. Notwithstanding the acceptance priority level, if any Notes
are purchased in the Offer, Notes tendered at or prior to the Early
Tender Time will be accepted for purchase in priority to Notes tendered
after the Early Tender Time and at or prior to the Expiration Time.
Pursuant to the terms of the Offer, the amount of Notes that will be
accepted for purchase is subject to the Tender Cap. Under certain
circumstances, the Company will accept tendered Notes of one or more of
the series on a pro rata basis as further described in the Offer to
Purchase.
The Company will pay the Full Tender Offer Consideration with respect to
Notes purchased pursuant to the Offer (including Notes tendered after
the Early Tender Time other than the 7.500% Notes, which the Company
currently intends, but is not obligated, to redeem in full). In
addition, holders that validly tender Notes that are accepted for
purchase by the Company will receive accrued and unpaid interest from,
and including, the last interest payment date for their tendered Notes
to, but not including, the settlement date for such Notes, in each case
rounded to the nearest cent.
The Withdrawal Deadline for the Offer was 5:00 p.m., New York City time,
on February 21, 2018, and has not been extended for any series of Notes.
The Offer will expire at 11:59 p.m., New York City time, on March 7,
2018, unless extended or earlier terminated by the Company, with respect
to any or all series of Notes.
The conditions to the Offer specified in the Offer to Purchase,
including the financing condition, have been satisfied.
Capitalized terms used in this press release and not defined herein have
the meanings given to them in the Offer to Purchase.
The Company currently intends to redeem all of the 7.500% Notes that
remain outstanding following the consummation of the Offer. Any such
redemption would be made in accordance with the terms of the indenture
governing the 7.500% Notes, which provides for a redemption price equal
to the greater of (i) 100% of their principal amount and (ii) the sum of
the present values of the remaining scheduled payments of principal and
interest thereon (not including any portion of such payments of interest
accrued as of the date of redemption), discounted to the date of
redemption on a semiannual basis at the Treasury Rate (as such term is
defined in the 7.500% Notes) plus 50 basis points, plus accrued and
unpaid interest to the date of redemption. The redemption price
has not yet been determined and it is possible that the redemption price
will be less or more than the applicable consideration for the 7.500%
Notes in the Offer. However, the Company is not obligated to
undertake any such redemption, and there can be no assurance that the
Company will redeem any 7.500% Notes that remain outstanding after
consummation of the Offer or of the timing of, or amount of any 7.500%
Notes subject to, any such redemption.
Goldman Sachs & Co. LLC, BofA Merrill Lynch, and J.P. Morgan are acting
as dealer managers for the Offer and HSBC and Wells Fargo Securities are
acting as co-dealer managers for the Offer. For additional information
regarding the terms of the Offer, please contact Goldman Sachs & Co. LLC
toll-free at (800) 828-3182 or collect at (212) 902-6595, BofA Merrill
Lynch toll-free at (888) 292-0070 or collect at (980) 387-3907 or J.P.
Morgan toll-free at (866) 834-4666 or collect at (212) 834-3260.
Requests for the Offer Documents may be directed to D.F. King & Co.,
Inc., which is acting as the Tender Agent and Information Agent for the
Offer, at (800) 290-6426 (toll-free) or by email at mck@dfking.com.
THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT AN
OFFER OR SOLICITATION TO PURCHASE NOTES. THE OFFER IS BEING MADE SOLELY
PURSUANT TO THE OFFER DOCUMENTS, WHICH SET FORTH THE COMPLETE TERMS OF
THE OFFER THAT HOLDERS OF THE NOTES SHOULD CAREFULLY READ PRIOR TO
MAKING ANY DECISION.
THE OFFER DOCUMENTS DO NOT CONSTITUTE AN OFFER OR SOLICITATION TO
PURCHASE NOTES IN ANY JURISDICTION IN WHICH, OR TO OR FROM ANY PERSON TO
OR FROM WHOM, IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION UNDER
APPLICABLE SECURITIES OR BLUE SKY LAWS. IN ANY JURISDICTION IN WHICH THE
SECURITIES, BLUE SKY OR OTHER LAWS REQUIRE THE OFFER TO BE MADE BY A
LICENSED BROKER OR DEALER, THE OFFER WILL BE DEEMED TO BE MADE ON BEHALF
OF THE COMPANY BY ONE OR MORE OF THE DEALER MANAGERS, IF ANY OF THE
DEALER MANAGERS ARE LICENSED BROKERS OR DEALERS UNDER THE LAWS OF SUCH
JURISDICTION, OR BY ONE OR MORE REGISTERED BROKERS OR DEALERS THAT ARE
LICENSED UNDER THE LAWS OF SUCH JURISDICTION.
About McKesson Corporation
McKesson Corporation, currently ranked 5th on the FORTUNE
500, is a global leader in healthcare supply chain management solutions,
retail pharmacy, community oncology and specialty care, and healthcare
information technology. McKesson partners with pharmaceutical
manufacturers, providers, pharmacies, governments and other
organizations in healthcare to help provide the right medicines, medical
products and healthcare services to the right patients at the right
time, safely and cost-effectively. United by our ICARE shared
principles, our employees work every day to innovate and deliver
opportunities that make our customers and partners more successful — all
for the better health of patients. McKesson has been named the “Most
Admired Company” in the healthcare wholesaler category by FORTUNE, a
“Best
Place to Work” by the Human Rights Campaign Foundation, and a top military-friendly
company by Military Friendly. For more information, visit www.mckesson.com.